Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
What: Alexza Pharmaceuticals
So what: This is disheartening news for Alexza shareholders with hopes for AZ-004, which would treat patients with schizophrenia or bipolar disorder. This doesn't spell the end for the drug because the company expects to meet with the FDA soon, but it at the very least hurts any planned launch timeline.
Now what: This puts Alexza in a tough spot not only with the drug but financially as well. The company had $14.2 million in cash at the end of the latest quarter and burned through $8.3 million in cash during the quarter. Even if AZ-004 achieves a positive outcome in coming quarters, shares may be diluted by further stock offerings. I would be cautious on Alexza until we hear positive news.
Interested in more info on Alexza Pharmaceuticals? Add it to your watchlist by clicking here.
Fool contributor Travis Hoium does not have a position in any company mentioned. Try any of our Foolish newsletter services free for 30 days. True to its name, The Motley Fool is made up of a motley assortment of writers and analysts, each with a unique perspective; sometimes we agree, sometimes we disagree, but we all believe in the power of learning from each other through our Foolish community. The Fool has a disclosure policy.